Proliv™ Rx

User Manual

Neurolief
Brain Innovation



IMPORTANT NOTICE

MANUFACTURER

Neurolief Ltd. 12 Giborei Israel

Netanya, Israel 4250412

Email: support@prolivrx.com Tel: +972-9-3730288

US ENTITY

10211 W Sample Road #109, Coral Springs,

Florida 33065 United States

Email: support@prolivrx.com Tel: +1-888-473-5484

PRESCRIPTION ONLY

℞ Only

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician/psychiatrist.

Patient's Health Care Provider (psychiatrist or physician) will review the patient's medical and depression history to help determine if the Neurolief Proliv™Rx Therapy is appropriate.

IMPORTANT

This user manual offers comprehensive and detailed instructions. The Proliv™Rx Care app provides a condensed version of these instructions, which may exclude certain details. If you ever have any doubts or uncertainties, we recommend referring to this user manual for guidance.

INDICATIONS FOR USE

The Proliv™Rx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for patients use at home or in clinic.
The device is a prescription only device.

USER MANUAL PURPOSES

This user manual provides the necessary instructions for safely operating your Proliv™Rx System in accordance with its function and intended use. It covers:

- Explanation of controls and indicators.
- Operation sequence.
- Maintenance and troubleshooting procedures.

SYSTEM SYMBOLS

The following describes the symbols used in this document and for this product.

Symbol	Description
	Consult instruction for use
	Class II equipment
	Prescription only Federal law restricts this device to sale by or on the order of a physician/psychiatrist
	Manufacturer
	Manufacturing date and country
	Type BF Applied part (front and back NeuroPorts)
	Serial number

	Catalog number
	Temperature limit
	Keep dry
	IP rating. Indicates the degree of protection. Proliv™Rx NeuroRouter is protected from limited dust ingress and from water spray from any direction
	RF transmitter
	Waste Electrical and Electronic Equipment Directive (WEEE)
	Single use
	Keep away from sunlight
	Do not use if package is damaged
	Atmosphere pressure limitation
	Humidity limitation
	Fragile, handle with care
	Medical device
	Home use
	USB DC wiring
	Caution
	Consult electronic instructions for use
	UDI
	Single patient - multiple use
	MR unsafe

Table 1: **System symbols**

CONVENTIONS USED IN THIS USER MANUAL

NOTE

Notes provide additional important information.

TIP

Tips indicate helpful information for using your Proliv™Rx.

WARNING!

Warnings indicate conditions or practices that may result in damage to the equipment or minor/moderate injury to the patient.

SAFETY INFORMATION

The following section details side effects observed during clinical trials of the Proliv™Rx System. It also includes warnings and precautions for Proliv™Rx System Therapy; these should be reviewed and discussed with your physician or psychiatrist to determine what, if any, precautions should be taken during your treatment with Proliv™Rx System.

The safety of the Proliv™Rx System was demonstrated in the aforementioned clinical trials.

In the MOOD trial, during the double-blind phase of the study, 74 adverse events were reported by 39 participants, 19 participants in the active arm (incidence: 30.16%, 19/63), and 20 participants in the sham arm (incidence: 32.79% ,20/61). Most adverse events reported by the active arm participants were mild (35 events), some moderate (9 events), and only 1 severe event.

In the same study phase, 31 events (out of 74) were considered related to the study device. Of these, 25 were in the active arm (20 mild and 5 moderate). Approximately 27% of the adverse events were headaches or migraines.

In the active arm, 15.87% (10/63) of study participants reported events classified as related to the study device, 9.52% of them Mild (6/63), and 6.35% Moderate (4/63). All but two events were successfully resolved. The remaining two cases of scalp itching and intermittent headaches/body aches were graded as mild and did not require follow-up.

In general, incidence of adverse events reported in the open label phase were similar to those reported in the double-blind phase by the active treatment group.

Finally, a single serious event of worsening depression symptoms was reported during the open label phase of the study.

No deaths or serious unanticipated device- related adverse events were reported among the participants in the clinical study.

Adherence to the instructions for use is important to minimize the risk of adverse events.

CONTRAINDICATIONS

The Proliv™Rx System is contraindicated for use in patients with:

- A history of intracranial surgery.

- Recent traumatic brain injury (TBI) (less than three months).
- A metal implant or shrapnel in their head, except for dental implants.
- An implanted neurostimulator or electronic device in your head such as a cochlear implant or brain pacemaker.
- A cardiac pacemaker or an implanted or wearable defibrillator.
- Skin lesions, scars, or inflammation at the region of the stimulating electrodes.

WARNINGS

- The Proliv™Rx device does not represent a substitution for your medication.
- Apply treatment only to intact, clean, healthy skin.
- Do not use the device on any other areas apart from the head.
- Keep the device out of reach of children. Small parts, such as the disposable pads, may be a choking hazard for small children.
- Do not use the device while driving or in conjunction with dangerous activity during which the user must be alert and focused (for example, while operating machinery).
- Do not use the device in the presence of electronic monitoring equipment that may not operate properly when the electrical stimulation device is in use.
- Do not use a device that shows signs of mechanical damage or loose parts.
- Do not modify this device or its accessories.
- Do not connect the Proliv™Rx device with other equipment.
- Use this device only with the supplied charger.
- Do not use any accessories, electrode pads, detachable parts, and materials that are not provided or recommended by Neurolief.
- Patients with active suicidal intent or plan should follow physician’s/psychiatrist’s instructions.
- If depression symptoms worsen, contact your physician.
- This device should only be used by patients whose clinical course is supervised by a medical provider.

PRECAUTIONS

- The long-term effects of chronic use of the device are unknown.
- The safety of electrical stimulation during pregnancy has not been established.
- Patients with suspected or diagnosed heart disease should follow precautions recommended by their physicians.
- Patients with suspected or diagnosed epilepsy should follow precautions recommended by their physicians.

- Do not use this device in locations subject to extreme high or low temperatures or humidity. Use within the temperature and humidity range according to the product's specifications (see Table 6).
- Do not use the device in the bath or shower.
- If the device does not function as described in this manual, stop using it and contact customer support.
- The Proliv™Rx device is designed for use by and on a single adult person. For hygiene reasons, the device should not be shared.
- Keep the device out of reach of pets.
- It is recommended that your mobile device be protected by a password (or other security mechanisms) to prevent unauthorized access to the Proliv™Rx device.

ADVERSE REACTIONS

Proliv™Rx, along with similar antidepressant treatments, have the potential for certain adverse reactions, which are detailed below. Adverse reactions reported with Proliv™Rx have been demonstrated in clinical trials to be mild to moderate and most are fully reversible upon cessation of device use. If adverse reactions persist, stop using the device and consult your physician/psychiatrist.

- Unpleasant sensation during treatment (e.g., pressure sensation at the stimulation position).
- A sensation of scalp numbness (paresthesia) during and after treatment.
- Persistent tingling, stinging, itching, or burning sensation after the treatment ends.
- Pain or discomfort.
- Skin reaction (e.g., irritation, lesion, or burn) beneath the electrodes. In such cases, treatment should be temporarily discontinued.
- Redness of the skin under or around the electrodes. Skin redness usually disappears within several hours after treatment.
- Sleepiness (somnolence), fatigue, or disruption in sleep patterns. Sedative effect during or after treatment.
- Dizziness during or after treatment.
- Headache/migraine
- Depression-related adverse events:
    - Mania.
    - Suicidal ideation
    - Worsening depression

WORSENING OF DEPRESSION OR INEFFECTIVE TREATMENT

As with any antidepressant treatment, there is a risk of your depression becoming worse before you begin to feel an improvement. Proliv™Rx Therapy may require up to 8 weeks of daily treatments before symptom improvement occurs. Make sure to discuss with your psychiatrist/physician the Proliv™Rx recommended treatment schedule. Contact your physician/psychiatrist if symptoms do not improve or if they get worse. Your physician/psychiatrist will monitor you for worsening depressive symptoms or signs or symptoms of suicidal behavior during the course of the treatment. Your family and caregivers should also be aware that if such behavioral changes appear, they should inform your physician/psychiatrist who will determine whether Proliv™Rx treatment should be discontinued and, if so, what other treatment options are available.

In the event of a medical emergency, please consult your healthcare provider on the appropriate course of action.

For more resources related to the treatment of psychiatric conditions, including recommendations for the public provided by professional healthcare organizations, please explore the American Psychological Association website (https://www.apa.org) or other relevant associations' websites.

NOTE

Please report to Neurolief Ltd. and the regulatory authority of your country of any serious incident that you encounter in relation to your Proliv™Rx

TABLE OF CONTENTS

1 Introducing Your Proliv™Rx

This chapter introduces your Proliv™Rx NeuroRouter and describes its components and contents.

NOTE

To ensure safe and proper usage, please review this entire user manual carefully before using your Proliv™Rx NeuroRouter.

Contact Customer Care at support@prolivrx.com or visit the Neurolief website at www.neurolief.com if you have any questions.

1.1 WHAT IS PROLIV™RX NEUROROUTER?

Proliv™Rx NeuroRouter is a non-invasive head-mounted medical device. It is designed to non-invasively trigger activation of relevant nerve branches in the head by externally applying mild electrical pulses through electrodes (NeuroPorts) placed on the forehead and occiput. These activated nerves serve as conductors of the signal to the brainstem and to relevant brain regions which participate in the regulation of mood, to treat major depressive disorder (MDD).



Figure 1: **Proliv™Rx NeuroRouter and the associated nerve branches**

Proliv™Rx NeuroRouter is a headset with integrated electrodes, called NeuroPorts, designed to trigger activation of relevant nerves. The on-board electronic circuit is adapted to deliver stimulation patterns to enhance proper nerve activation. Proliv™Rx can be worn comfortably and adjusts to various head sizes and contours. Each time it is worn, the six NeuroPorts are placed over the underlying nerves. The four NeuroPorts on the forehead trigger branches of the Trigeminal nerve and the two NeuroPorts at the back of the head trigger the greater Occipital nerve.

Your Proliv™Rx NeuroRouter incorporates an on-board user interface to turn it on and/or off. It provides visual and auditory indications to indicate when the NeuroRouter is on/off and battery status.

Your Proliv™Rx NeuroRouter communicates via Bluetooth link with your Proliv™Rx Care app, a dedicated mobile application on the user's smartphone. Proliv™Rx Care is required in order to operate and control your Proliv™Rx NeuroRouter. Therefore, Proliv™Rx Care should be downloaded from the App Store/Google Play store before initial use of your Proliv™Rx NeuroRouter. Once paired, you can start a session, control your Proliv™Rx, and check its status using the mobile app.

NOTE

Your Proliv™Rx provides sufficient Quality of Service (QoS) across its BLE internal network for its intended use

NOTE

Your Proliv™Rx BLE internal network utilizes encryption of the data that is being transferred.

1.2 YOUR PROLIV™RX KIT

Your Proliv™Rx kit includes the components presented in Table 2: Contents of Proliv™Rx kit.

Contents of Proliv™Rx kit	
Proliv™Rx NeuroRouter	
Proliv™Rx Charger	
Proliv™Rx Port Pads Daily Pack (4 front Port Pads and 2 back Port Pads)	
Spray Bottle	
Proliv™Rx Quick Guide	
Proliv™Rx Case	

Table 2: **Contents of Proliv™Rx kit**

Do not use accessories other than those provided with your Proliv™Rx kit.

1.3 YOUR PROLIV™RX NEUROROUTER

Your Proliv™Rx NeuroRouter is designed to be comfortably worn on the head during treatment. It features six NeuroPorts – four in the front of the Proliv™Rx (forehead) and two in the back (occiput). It includes two flexible arms that go under the hair while the Proliv™Rx is worn. A size adjustment mechanism is located on both sides. The power button and light indicators are positioned on the front part of the Proliv™Rx.



Figure 2: **Proliv™Rx - side view**



Figure 3: **Proliv™Rx - front view**

Indicator Light	Meaning
Steady Blue	Proliv™Rx is ON, which means that the power button has been pressed, and your Proliv™Rx is in standby mode, ready for use.
Flashing Blue	Treatment is active.
Steady Red	Device malfunction.
Flashing Red	Poor contact during treatment.
Steady Yellow	Fully charged and connected to the charger
Flashing Yellow	Battery depleted/charging

Table 3: **Proliv™Rx status and battery indications**

Your Proliv™Rx also emits sounds (beeps) to indicate its status.

Sound	Meaning
Short beep	Your Proliv™Rx turned ON.
Three beeps	There is a poor contact
Two beeps	Your Proliv™Rx turned OFF.
Short beep	The treatment was automatically ended after 40 minutes.

Table 4: **Proliv™Rx sound indications**

NOTE

Your Proliv™Rx does not store any sensitive user/patient data.

1.4 PROLIV™RX CARE APP

Proliv™Rx Care is essential for using the product.

1. It features tutorials and troubleshooting tips to ensure your Proliv™Rx is worn correctly.
2. It serves as a control interface for your Proliv™Rx NeuroRouter.
3. It guides you through the treatment phases.
4. It offers a biweekly self-assessment questionnaire.
5. It provides reports that include a summary of your treatment and results of the self-assessment questionnaires, which can be shared with your physician or psychiatrist.

1.5 PROLIV™RX TREATMENT PHASES

Proliv™Rx therapy includes two consecutive treatment phases designed to support your initial adjustment to the treatment and your subsequent treatment phase. Your physician/psychiatrist may prescribe additional treatment phases aligned to your medical condition and outline them in your prescription.

The following treatment phases are available:

1. **NeuroPrime phase:** Designed for new patients, this introductory phase helps familiarize you with the product, daily treatment routine, and treatment sensation. This phase is assigned automatically in the first week of product use. It contains two daily sessions with a gradually increased session duration and intensity level. By the end of this phase, you should reach a regular session duration and attain your highest comfortable intensity level.
2. **NeuroRestore phase:** This phase will be automatically assigned after you complete the NeuroPrime phase. It consists of two daily sessions, each lasting 40 minutes, for a period of 8 weeks. During this phase, you should aim for your sessions to be conducted at your highest comfortable level of intensity.

2 Getting started with Proliv™Rx

2.1 PRELIMINARY STEPS

Before using your Proliv™Rx for the first time, several preliminary steps must be performed.

1. Charge your Proliv™Rx NeuroRouter. It takes up to four hours to fully charge the battery. A fully charged battery is sufficient for approximately five hours of treatment. Connect the magnetic connector of the charging cable to the charging port on your Proliv™Rx. The charging port is located at the bottom of your Proliv™Rx.

WARNING!

Only use the power supply and charging cable supplied with your Proliv™Rx.



Figure 4: **Proliv™Rx magnetic connector and charging port**

NOTE

Check the charging port and cable are not wet before charging your Proliv™Rx.

NOTE

It is not possible to use your Proliv™Rx while it is connected to the charger.

2. **Download Proliv™Rx Care** to your smartphone from App Store or Google Play. Proliv™Rx Care is compatible with smartphones running either Apple iOS15 and above or Android 12 and above. Never try to connect your Proliv™Rx NeuroRouter with a mobile application other than the Neurolief-certified application available on the Apple/Google store.

Figure 5: **Proliv™Rx Care app**

3. **Open Proliv™Rx Care and follow the instructions** to create your new account. A verification code will be sent to you to confirm your account.

NOTE

The information saved within the app is securely stored in the cloud. If you re-install the Proliv™Rx app, your information will be securely re-accessed upon login. The app only stores your registration information

4. **Pair your Proliv™Rx NeuroRouter with the Proliv™Rx Care app**. Turn your Proliv™Rx ON and make sure that Bluetooth is enabled on your smartphone. Follow the instructions in the app to pair your Proliv™Rx.
5. **Watch the mandatory self on-boarding tutorials** where you'll get familiarized with your Proliv™Rx NeuroRouter and app. You will learn how to adjust your Proliv™Rx to fit your head and prepare for treatment. While watching the videos, follow the instructions and perform the required actions using your own Proliv™Rx.

NOTE

You must complete watching a tutorial video (once) before moving to the next one.

NOTE

The tutorials are always available for you on the “More” screen within the app.

6. Upon watching all the tutorials and adjusting your Proliv™Rx to fit your head, tap **on “Let’s get started”** to go to the homepage and **start your first treatment session.**

2.2 ADJUSTING YOUR PROLIV™RX NEUROROUTER TO FIT YOUR HEAD

Finding your Proliv™Rx size is a one-time process. Once you’ve got the right size, you’re ready for all future sessions.

The arms of your Proliv™Rx are adjustable. You can extend them by pressing the adjustment buttons and pulling the arms. The dots and numbers on the inside of the arms indicate the size, with each dot representing half-size.



Figure 6: **Arms size, Proliv™Rx**

1. To find your size, first extend your Proliv™Rx before placing it on your head. Once it’s positioned correctly, tighten it. Men should start by setting their Proliv™Rx to the largest size with the arms fully open. Women can start from size seven.

2. To optimize the effectiveness of your treatment, it's important to position your Proliv™Rx correctly. Here are a few key points to keep in mind:
   - Your Proliv™Rx should be centered with your nose.
   - The front should touch your eyebrows.
   - The arms should rest half an inch above your ears, not touching them.
   - The magnetic clasp at the back of your Proliv™Rx must rest half an inch above the bony bump at the back of your head. You can find this bone by running your index finger straight along your spine and then up along the back of your head until you reach the most prominent bump. Make sure your Proliv™Rx is right above, not below, the bump.



Figure 7: **Correct position of Proliv™Rx**

If you have long hair, this is another vital point to remember:

- **Minimize the amount of hair** between the Port Pads and your scalp. Hair can disrupt the skin-NeuroPorts interface, impacting the stimulation. Use the magnet ends to penetrate your hair while placing your Proliv™Rx. Keep the ends close to your scalp while you slide them through your hair, creating a parting all the way back.

3. Ensure your Proliv™Rx is upright: Examine the inside of each arm to check if it is the left or right side and understand the correct orientation.



Figure 8: **Right arm side, Proliv™Rx**

4. Open the magnetic clasp, position your index fingers on the back NeuroPort covers, place the arm tips above your ears, and slide them all the way back while keeping them parallel to the floor. **Make sure the arms penetrate under your hair while staying close to the scalp**. The magnet ends should connect at the back.



Figure 9: **Placing Proliv™Rx on the head**

5. To tighten your Proliv™Rx to fit your head, place your index fingers on the grip lines toward the front of the Proliv™Rx and your thumbs on the grip dots toward the back. Gradually tighten your Proliv™Rx, keeping it symmetrical and making sure the magnet ends are still connected.



Figure 10: **Tightening the arms of Proliv™Rx**

After tightening the arms of your Proliv™Rx, remember to check it's still positioned correctly, as mentioned in step 2 and shown in Figure 7 above.

- Your Proliv™Rx should feel very tight. To check the fit, gently move the front of the device up and down - your forehead skin should move together with your Proliv™Rx. However, you should still be able to move your neck, head, and face comfortably without disconnecting the magnet ends.

NOTE

After removing your Proliv™Rx, you may notice a pressure mark. This will gradually fade and is not a cause for concern.

Take your Proliv™Rx off your head and check the arms are symmetrical. They should either be the same size or have up to a one-unit difference between them. For instance, if one arm is size seven while the other is size five, adjust both arms to size six, with size six becoming your designated size.



Figure 11: **The Proliv™Rx arms are symmetrical**

TIP

Remember to note down your size for future treatment sessions.

3 Using Your Proliv™Rx

This chapter describes how to perform a treatment session with Proliv™Rx System.

3.1 PREPARING FOR A TREATMENT SESSION

1. Begin preparing for a treatment day by opening a packet of Proliv™Rx Port Pads. Insert the four small pads at the front of your Proliv™Rx and the two larger ones at the back.

NOTE

Contact your supplier when you need additional Port Pads



Figure 12: **Front Port Pads**



Figure 13: **Back Port Pads**

2. Before each session, clean your forehead with a wipe or wash it with soap and water to improve NeuroPorts-skin contact.
3. Before every session, wet the Port Pads with tap water using the provided spray bottle from your Proliv™Rx kit. Hold the nozzle against the pad (which is inserted into the NeuroPort socket) and press down fully. The pad absorbs water faster when the nozzle is held against it. Spray each front pad five times, and each back pad ten times. **The wetter the pads, the better**. Ensure the Port Pads are wet enough by pressing on each pad. You should feel and see droplets of water coming out.

TIP

Quick and short presses of the nozzle won't release enough water, so press it fully against the Port Pads.

WARNING!

Do not wet the pads by rinsing your Proliv™Rx under running tap water.



Figure 14: **Wetting the Port Pads**

4. Next, let down your hair and remove any hair accessories. If you have an eyebrow ring, you'll need to take it out before your session as it can interfere with the NeuroPorts contact. If feels comfortable for you, you can wear your glasses while using your Proliv™Rx.
5. Place your Proliv™Rx on your head, ensuring that it **penetrates under your hair** and stays close to your scalp. Keep in mind the positioning rules, as detailed in section 2.2 above.
6. Finally, press on the **back NeuroPort covers** until you feel moisture on your scalp. This enables the stimulation to pass through any hair between the pads and your scalp.

Figure 15: **Pressing the back NeuroPort covers to release moisture**

3.2 CONDUCTING A TREATMENT SESSION

NOTE

Remember to press the back NeuroPorts covers before every treatment session.

1. Turn Your Proliv™Rx ON by pressing the device's power button.
2. Open Proliv™Rx Care and make sure Your Proliv™Rx NeuroRouter is connected. The status bar should indicate "Ready for use".
3. Look for new messages or tasks on the "Home" page before starting a treatment session. Here you can also see your treatment plan and records for the week.
4. To start, tap the "Start session" button.
5. Proliv™Rx placement reminders will appear on the screen. Once you feel ready, tap "OK". You can skip this step in future sessions by tapping the "Don't show again" checkbox.
6. Proliv™Rx System runs a contact check before each treatment session. Once all NeuroPorts have established good contact, the session begins automatically. Follow the in-app troubleshooting guide to fix any contact issues. The app also notifies you if Your Proliv™Rx is worn upside down.

7. At the beginning of the session, the intensity will gradually and automatically increase up to a predefined level. As the intensity increases, you will feel a tingling sensation around the NeuroPorts. The stimulation should always feel comfortable and never painful. You can stop the automatic intensity increase at any time by pressing 'Stop auto-increase'.
8. Once the automatic increase ends, continue gradually increasing the intensity level until you reach the highest level that is still comfortable for you. You may decrease the intensity level at any time during the session. As you increase the intensity you may feel a tingling, stinging and/or itching sensation, and as the session continues you may experience scalp numbness. These are normal sensations for this type of treatment. The most effective treatment will be a treatment whose intensity level is as high as possible for you **but is still comfortable**.

TIP

As the session progresses, you may become accustomed to the stimulation. If it feels comfortable, you can try increasing the intensity further.

NOTE

Although the optimal intensity is 25 and above, stimulation must stay comfortable, it may take time to adjust to the stimulation. The app will guide you through the gradual adjustment process.

9. To pause the session, tap the “Pause session” button. The stimulation will immediately stop, and the session timer will pause as well. You may now decide whether to resume or end the session. If paused for 20 minutes, the session will end automatically.

NOTE

When resuming a session, the system will run the contact check process again. The intensity level is automatically increased to a predefined level. Continue raising the intensity level manually to the highest comfortable level.

NOTE

If you decide to end a session before its completion, you will not be able to return to the session and complete it later.

10. The treatment session will automatically end when the time is up. You may now remove your Proliv™Rx from your head by detaching the magnet ends.
11. Turn off your Proliv™Rx by pressing the power button on the NeuroRouter. If it is not turned off, it will switch off automatically after 20 minutes.
12. At the end of the session, a session summary will be displayed on the app’s screen.
13. Remove the Port Pads and discard them at the end of each day of use.

TIP

It is highly recommended to increase the intensity level gradually. In each level increase, give yourself a few moments to check how it feels before moving up to the next level. As the treatment continues and you get used to how the stimulation feels, try increasing the intensity level while making sure it's still comfortable for you.

TIP

It is recommended to split the daily treatment sessions into morning and evening sessions to give your skin some rest between sessions

4 Proliv™Rx Care App

4.1 HOME

From “Home”, the app’s homepage, you can initiate a treatment session and view your daily and weekly conducted and scheduled sessions.

4.2 REPORTS

The “Reports” page provides you with statistical information regarding your therapy progress. An option to export report in a PDF format, in order to send it to your health care provider, is also available from this page.

The “Reports” page includes the following data presented by graphs:

1. Self-assessment questionnaire: Displays the total scores of the biweekly self-report questionnaires over time. The baseline is defined as your score when you start Proliv™Rx therapy.
2. Treatment consistency: The score represents your treatment compliance in terms of number of treatment sessions, by displaying the percentage of performed treatment sessions out of the planned sessions for a treatment week. Current week’s score will be presented only at the end of the week.
3. Average intensity: The score represents your treatment compliance in terms of intensity, by displaying the average intensity level used in treatment sessions during a treatment week. Current week’s score will be presented only at the end of the week.
4. Average session time: The score represents your treatments compliance in terms of length of treatment sessions, by displaying the average session time for treatment sessions performed during a treatment week. Current week’s score will be presented only at the end of the week.

NOTE

Statistical data from your treatment will be available only after you complete the NeuroPrime phase.

4.3 HELP & TIPS

The “Help & Tips” page provides you with tips recommended for you. Based on your treatment progression, when the system identifies a tip that might help you improve the effectiveness of the treatment, a new tip will appear on this page. A dot indicator will inform you that you have a new tip.

In this page you will also find answers to common questions Proliv™Rx users have.

4.4 MORE

The “More” page provides access to some of the technical aspects of the product:

1. Profile: User account details, NeuroRouter details and your therapy phases.
2. Tutorials & Manuals: Links to the video tutorials and to the product’s manuals (online PDFs), contraindications, warnings and precautions.
3. About: Privacy policy, user agreement and information regarding Your Proliv™Rx Care app.

4.5 QUESTIONNAIRE

While using Your Proliv™Rx System, you will be asked to complete a mandatory biweekly digital depression self-assessment questionnaire (professionally known as the "PHQ-9") to help you, and your physician/psychiatrist track your depression status. The questionnaire consists of 9 questions, each addressing a common depression symptom. For each question, you rate how often you've experienced that symptom over the past 2 weeks, using a scale that ranges from "not at all" to "nearly every day". You can learn more about the PHQ-9 questionnaire in the app. Prior to your first Proliv™Rx session and when it’s time to complete a follow up questionnaire, a message will appear on the app’s screen to allow you to fill in the questionnaire. To initiate your next treatment session, you are required to complete the questionnaire.

NOTE

To submit and save your self-report questionnaire data to the cloud, your smartphone must be connected to the internet.

5 Troubleshooting and Maintenance

5.1 TROUBLESHOOTING

This section offers troubleshooting for various issues with Proliv™Rx System.

If a technical problem is not covered below or cannot be resolved by the suggested solutions, please contact Proliv™Rx Customer Care.

Problem/Symptom	Troubleshooting steps
Proliv™Rx Care App is unable to connect to my Proliv™Rx NeuroRouter	• Make sure Your Proliv™Rx is charged. • Make sure Your Proliv™Rx is turned on. • Make sure Bluetooth is enabled on your smartphone. • Make sure the smartphone and the NeuroRouter are within close enough proximity to each other (five meters or less). • Make sure you correctly entered the last three digits of your NeuroRouter's Serial Number. The S/N label is located on the bottom front side of the device. • On some mobile phone models, establishing the connection may take a few extra seconds. Please wait a moment before assuming the connection was unsuccessful. If the problem persists, contact Proliv™Rx Customer Care.
Three beeps sounded during the treatment and the session was paused.	When poor contact occurs, the status indicator light flashes red, Your Proliv™Rx beeps, and the treatment session is paused. To resolve the problem, tap “Resume session” to initiate the contact check process. The app will indicate which NeuroPorts have poor contact and provide instructions to improve the contact.

	Optional solutions: • Press on the back NeuroPort covers to release moisture. • Ensure the magnet ends are closed. • Make sure your Proliv™Rx is secured tightly enough on your head. • Ensure the Port Pads are completely soaked. • Make sure you are using fresh Port Pads.
Proliv™Rx NeuroRouter does not turn ON.	**Optional solutions:** • The battery is depleted. Charge your Proliv™Rx, as described in the Getting started with Proliv™Rx section. • Proliv™Rx is connected to a charger. Disconnect from the charger and turn your Proliv™Rx on.
The status indicator light (~) is steady red.	Indicates a NeuroRouter malfunction. Contact Proliv™Rx Customer Care.
Not all content is displayed properly on screen	The display size setting on your mobile phone might not be supported. Go to the Display Size setting on your phone and change it to a smaller size.
Not able to resume a session after clicking Poor contact notification on the phone	In a specific scenario, you might not be able to resume a treatment session after receiving a 'Poor contact' message from the Proliv™Rx Care app. In this case, close the app and re-open it. Then, follow the on-screen instructions to fix the contact issues and complete the session.

Table 5: **Proliv™Rx product troubleshooting**

5.2 CLEANING AND MAINTENANCE

- There are no parts that need regular service or technical maintenance.
- Clean your Proliv™Rx with a wet cloth periodically, as visibly required.
- Do not use solvents of any kind (acetone, petrolatum, etc.) on your Proliv™Rx
- Dispose of the Port Pads at the end of a treatment day.
- When your Proliv™Rx is not in use, make sure the arms are not connected to each other by the magnets.

NOTE

Leaving wet Port Pads in the NeuroRouter overnight may degrade the NeuroPorts conductivity.

TIP

Store your Proliv™Rx in its case when not in use.

5.3 DISPOSAL

- Discard used Port Pads in regular trash receptacles after each daily use.
- Follow national, state, and local regulations for the proper disposal of your Proliv™Rx NeuroRouter, as it contains a Lithium-Ion battery.

6 Cybersecurity

Recognizing the concern of our customers and rapidly growing cybersecurity threats, Neurolief is committed to the deployment of a comprehensive security strategy that assures the safety of our product, business, and personal data.

Neurolief uses industry-standard instructions to protect the Proliv™Rx system, including its NeuroRouter, mobile app, system servers hosted on Amazon Web Services, and the data on those servers.

All data transmitted from the mobile app to the NeuroRouter, or the system servers is encrypted using industry-standard **Data Encryption** protocols. We **Authenticate** our users via SMS verification code, **Control Access** to the NeuroRouter by allowing a single connection to a mobile device. We ensure **Confidentiality** by not holding any Personally Identifiable Information on your Proliv™Rx NeuroRouter and mobile app. We **Backup** our servers regularly to minimize the risk of data loss. Neurolief also provides **Regular Updates** to the mobile app and servers to address new security vulnerabilities and potential threats. All integration, backup and restore actions are performed only by the company's technicians, following validation protocols which include security configuration and backup functions.



Figure 16: **Implemented Cybersecurity controls in Proliv™Rx**

We also implement **Hardware Protection** circuits that limit the voltage and delivered charge, to ensure your safety. These circuits cannot be controlled by any external source, providing a reliable safeguard against manipulation.

Proliv™Rx Care is installed on a personal phone. The user is responsible for the mobile phone's security. We provide you with best practices and recommendations to increase the cybersecurity of your mobile phone and your Proliv™Rx mobile app and NeuroRouter.

- **Authorized Device Use:** Ensure that your Proliv™Rx is not left unsecured when not in use, to prevent unauthorized personnel use.
- **Password Management**: Use strong, unique passwords on your mobile phone and change them regularly.
- **Software Updates**: Keep the mobile operating system on your mobile phone up to date. Ensure that your Proliv™Rx software is always up to date by enabling automatic updates or visit the official mobile app store regularly to check for updates. Download Proliv™Rx Care only from the official app stores.
- **Network Security**: Connect the mobile device only to secure, trusted networks. Avoid using public Wi-Fi when operating your Proliv™Rx.
- **Incident Reporting**: Immediately report any suspicious activity or security incidents to Proliv™Rx Customer Service team (see contact details below).

The company maintains architectural diagrams and a bill of materials (SBOM) of its software. This information may be available for certain customers per request. For more information, contact our Customer Service team, per details provided below.

INCIDENT RESPONSE

In the event of a cybersecurity incident, follow these steps:

1. **Disconnect**: Immediately turn off your Proliv™Rx manually and disconnect the mobile device from the network to prevent further unauthorized access.
2. **Report**: Notify the Proliv™Rx Customer Service team and provide detailed information about the incident.
3. **Follow Instructions**: Follow the instructions provided by the Customer Service team to mitigate the impact and restore Proliv™Rx functionality.
4. The company will inform the relevant users when a vulnerability fix is ready and available for installation by publishing an advisory in the company's website, In the event of a critical update, registered users will also be directly notified via email or phone.
   The following information will be disclosed:

- Overview of the identified vulnerability, its nature, potential impact, affected devices and software versions.
- Actions taken to mitigate the vulnerability, including details on software updates, or other remediation measures.
- Information on the risk assessment of the vulnerability, outlining the potential risk to patient safety, data integrity, and overall Proliv™Rx functionality if any.

CONTACT INFORMATION

For any cybersecurity-related concerns or questions, please contact our Customer Care team at support@prolivrx.com or call our hotline at +1-888-473-5484.

END OF SERVICE

Upon reaching the **End of Service (EOS)** date for the Proliv™Rx System, the following measures will take effect:

1. User Notification and Access Termination

- You will receive prior notification before service discontinuation.
- On the EOS date, access to the Proliv™Rx System, including the NeuroRouter, mobile app, and cloud services, will be permanently disabled.

2. Data Handling

- Device: The Proliv™Rx NeuroRouter does not store personal data, eliminating any risk of data exposure.
- Mobile App: Treatment data is temporarily stored and deleted after syncing with the cloud. Upon service termination, the app will no longer be accessible.
- Cloud Storage: Medical data will be securely retained by Neurolief per legal and regulatory requirements. After the mandatory retention period, all stored data will be permanently destroyed.

3. Termination of Support and Updates

- No further software updates, security patches, or technical support will be provided.
- Neurolief's Customer Service team will no longer be available for troubleshooting or assistance.

For further inquiries regarding the end-of-service process, please contact our Customer Service team before the EOS date.

7 Technical Specifications

This chapter describes the technical specifications of the Proliv™Rx System.

Operating Conditions	
Temperature	+41°F to +104°F/+5°C to +40°C
Relative Humidity	15% to 90%
Atmospheric Pressure	10.1PSI to 15.3 PSI/700 hPa to 1060 hPa
IP Classification	IP54

Transport and Storage Conditions	
Temperature	14°F to +131°F/-10°C to +55°C
Relative Humidity	Less than 90% (non-condensing)
Atmospheric Pressure	10.1PSI to 15.3 PSI/700 hPa to 1060 hPa

Electrical Specifications	
Number of Stimulation Channels	3 (2 Trigeminal, 1 Occipital)
Constant Current	Yes
Waveform	Symmetrical rectangular biphasic pulse, 100% compensated

Maximum Current – Trigeminal	3.95 mA (per channel)
Maximum Current – Occipital	10.66 mA
Maximum Phase Duration	Front NeuroPorts: 300 µsec Back NeuroPorts: 200 µsec
Maximum Frequency	80 Hz
Maximal Voltage	@500ohms – 1.9V front NeuroPorts/5.3V back NeuroPorts @2,000ohms – 7.9V front NeuroPorts/21.3V back NeuroPorts @10,000ohms – 39.5V front NeuroPorts/100V back NeuroPorts
Maximum Charge per Phase	1.19 µC front NeuroPorts /2.12 µC back NeuroPorts
Maximum Current Density (mA/cm^2, peak)	0.64 front NeuroPorts / 1.14 back NeuroPorts
Maximum Current Density (mA/cm^2, r.m.s.) @500 ohms	0.031 front NeuroPorts / 0.036 back NeuroPorts
Maximum Average Power Density (W/cm^2)	0.000003 front NeuroPorts/0.000006 back NeuroPorts
Maximum Rise Time	≤5 µsec
Timer	Up to 40 minutes
Power Source	
Battery Type	Rechargeable 3.7V Li-Po battery, 200 mAh
Battery Life	500 charge cycles
Charging Source	AC line adapter

Wall Adapter Input	100–240 VAC, 50/60 Hz, 0.3 A

Radio Transceiver Properties

Frequency Band	2,400–2,483.5 MHz
Maximum Emitted Radiation Power	7.5dBm
Modulation	GFSK
Radio Protocol	BLE type 4.2

Device

Number of NeuroPorts	6 (4 forehead NeuroPorts and 2 occiput NeuroPorts).
Replaceable Port Pads	One packed unit includes 6 pads. Contact your supplier to order more.
Size	Minimum Circumference (Adjusted to Smallest Head Size) – 20”/ 510mm. Maximum Circumference (Adjusted to Largest Head Size) – 23½”/600mm
Dimensions	8” x 5” x 1½” / 209mm x 128mm x 39mm
Weight	0.2 lb / 90 g

Device Lifetime

3 years

Software application (app)

iOS version 15 or above, Android version 12 or above

Encrypted communication channels	BLE- communication between app and NeuroRouter REST over HTTPS- communication between app and cloud services

Table 6: **Technical specifications**

8 Electromagnetic Compatibility

Proliv™Rx is intended for use in the electromagnetic environment specified below.
The user should ensure that it is used in such an environment.

Emissions Test	Compliance	Electromagnetic Environment – Guidance
RF Emissions CISPR 11	**Group1 Class B**	Proliv™Rx uses Radio Frequency (RF) energy only for its internal function. Therefore, its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment. Proliv™Rx is suitable for use in all establishments, including domestic establishments and those directly connected to the public low-voltage power supply network that supplies buildings used for domestic purposes.
Harmonic Emissions IEC 61000-3-2	**Class A**	
Voltage Fluctuations and Flicker IEC 61000-3-3:2013	**Complies**	

Table 7: **Manufacturer's declaration – Electromagnetic emissions**

Immunity Test	IEC 60601 Test Level	Compliance Level	Electromagnetic Environment – Guidance
Electrostatic Discharge (ESD) IEC 61000-4-2	• 8kV contact • 2, 4, 8, 15kV air	• 8kV contact • 2, 4, 8, 15kV air	Floors should be wood, concrete or ceramic tile. If floors are covered with synthetic material, the relative humidity should be at least 30%.
Electrical fast transient/burst IEC 61000-4-4	• 1 kV for mains power ports	Evaluated during AC/DC adapter approval	Mains power quality should be that of a typical domestic establishment.
Fast Surge Immunity IEC 61000-4-5	• 1 kV line(s) to line(s) • 2 kV line(s) to earth	Evaluated during AC/DC adapter approval	
Voltage dips, short interruptions and voltage variations on power supply input lines IEC 61000-4-11	• 0% UT – 0.5 cycle at 0°, 45°, 90°, 135°,180°, 225°, 270° and 315° • 0% UT – 1 cycle • 70% UT – 25/30 cycles • Single phase at 0° 0% UT – 250/300 cycles	Evaluated during AC/DC adapter approval	Mains power quality should be that of a typical domestic establishment.
Power frequency magnetic field IEC 61000-4-8	50/60 Hz, 1 A/m	Not applicable	Power frequency magnetic fields should be at levels characteristic of a typical location in a typical commercial or hospital environment.
Conducted RF IEC 61000-4-6 Radiated RF IEC 61000-4-3	3 Vrms 150kHz to 80MHz 10 V/m from 80 MHz to 2.7 GHz	3 Vrms 150kHz to 80MHz 10 V/m from 80 MHz to 2.7 GHz	Portable and mobile RF communications equipment should be used no closer to any part of the Proliv™Rx, including cables, than the recommended separation distance calculated from the equation applicable to the frequency of the transmitter. Recommended separation distance $d=1.17\sqrt{p}$ 150 kHz to 80 MHz $d=1.2\sqrt{p}$ 80 MHz to 800 MHz $d=2.3\sqrt{p}$ 800 MHz to 2.5 GHz Where *P* is the maximum output power rating of the transmitter, in watts (W), according to the transmitter manufacturer and *d* is the recommended separation distance in meters (m). Field strengths from fixed RF transmitters, as determined by an electromagnetic site survey, should be less than the compliance level in each frequency range. Interference may occur in the vicinity of equipment marked with the following symbol – 

Table 8: **Manufacturer's declaration – Electromagnetic immunity**

Rated Maximum Output Power of Transmitter (W)	Separation Distance According to Frequency of Transmitter (m)		
	150 kHz to 80 MHz $d=1.17\sqrt{p}$	80 MHz to 800 MHz $d=1.2\sqrt{p}$	800 MHz to 2.5 GHz $d=2.3\sqrt{p}$
0.01	0.12	0.12	0.23
0.1	0.37	0.38	0.73
1	1.17	1.2	2.3
10	3.7	3.8	7.3
100	11.7	12	23

Table 9: **Recommended separation distances between portable and mobile RF communications equipment and the Proliv™Rx**

ELECTROMAGNETIC COMPATIBILITY WARNINGS

Proliv™Rx NeuroRouter is approved according to electromagnetic compatibility (EMC) safety standard EN 60601-1-2. It is designed to be used in typical domestic environments –

- Radiated or conducted electromagnetic signals may impair Proliv™Rx essential performance, and incorrect output that exceeds the device's specifications may occur.
- Exposure to electromagnetic interference may result in temporary disruption of communication between the device and the mobile app; during such events, stimulation is designed to continue without interruption. Communication is expected to be restored automatically once the electromagnetic interference is resolved. If discomfort occurs during treatment and app control is not available, the treatment can be stopped by pressing the device's Main button.
- Use of this device adjacent to or stacked with other equipment should be avoided because it could result in improper operation. If such use is necessary, this device and the other equipment should be observed to verify that they are operating properly.
- Use of accessories, transducers, and cables other than those specified or provided by the manufacturer of this equipment could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.
- Portable RF communications equipment (including peripherals such as antenna cables and external antennas) and Wireless Power Transfer (WPT) equipment should be used no closer than 30 cm (12 inches) to any part of the Proliv™Rx device, including cables specified by the manufacturer. Otherwise, degradation of the performance of this equipment could result.
- The Device should not be used around strong magnetic fields, e.g. near an MRI machine.

9 FCC Compliance

This Proliv™Rx NeuroRouter complies with Part 15 of the Federal Communications Commission (FCC) Rules. Operation is subject to the following conditions –

1. This device may not cause harmful interference.
2. This device must accept any interference received, including interference that may cause undesired operation.

FCC ID: 2AO9M-01

WARNING!

Modifications not expressly approved by the manufacturer could void the user authority to operate the equipment under FCC Rules.

A distance of at least 0.25 cm between the equipment and all persons should be maintained during the operation of the equipment.

FCC COMPLIANCE STATEMENT

This device has been tested and found to comply with the limits for a Class B digital device, pursuant to Part 15 of the FCC Rules. These limits are designed to provide reasonable protection against harmful interference in residential installations. This equipment generates, uses, and can radiate radio frequency energy and, if not installed and used in accordance with the instructions, it may cause harmful interference to radio and television reception.

However, there is no guarantee that interference will not occur in a particular installation. If this device does cause such interference, which can be verified by turning the Proliv™Rx off and on, the user is encouraged to eliminate the interference by one or more of the following measures:

1. Re-orient or re-locate the receiving antenna.
2. Increase the distance between the device and the receiver.
3. Connect the device to an outlet on a circuit different from the one that supplies power to the receiver.
4. Consult the dealer or an experienced radio/TV technician.

10 Summary of Clinical Data

Proliv™Rx as an adjunctive treatment for Major Depressive Disorder (MDD) was studied in two clinical trials.

FEASIBILITY STUDY

The first trial, a feasibility study, was a prospective open label study which included 29 enrolled participants aged 21 to 65, diagnosed with depression, who had failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Of the 29 participants, 24 completed the study.

The primary efficacy outcome of the trial was the change in depression symptoms from study baseline (initial score before treatment) to the end of 6 weeks of daily Proliv™Rx treatment. This change was assessed by each participant's physician using the Hamilton Depression Rating Scale (HDRS21). Participants experienced improvement in symptoms, with an average HDRS21 reduction of 10 points, representing a 40% average improvement in depression scores. In total, 67% (16/24) of the participants improved by 40% or more, and 42% (10/24) of the participants improved by 50% or more. Regarding safety, there were no serious adverse events reported during the study, and all adverse events were mild to moderate, suggesting a favorable safety profile for the studied therapy.

The feasibility trial was used to mainly assess safety and could not be used to determine treatment effectiveness due to the lack of control group.

MOOD STUDY

The second trial, the pivotal trial, was a prospective, randomized, parallel-group, sham-controlled study with an open label phase - the MOOD trial. The primary outcome was assessed from the start of the study through the first 8 weeks, when the two-group structure and blinding were maintained.

MOOD study analysis populations

As is common in most studies, the MOOD study results were analyzed in different analysis populations (different ways of grouping participants for analysis).

The Intent-to-Treat (ITT) population (n=124): Included all participants who were randomized and attempted any use of the investigational device, regardless of significant protocol deviations or lack of follow-up data.

The Modified Intent to Treat (mITT) population (n=97): This was the primary analysis population that was pre-specified by the protocol for assessing effectiveness (main way the study judged if the treatment worked). It included all participants from the ITT population who used the device for at least 40 minutes per day, 5 days per week, over 8 weeks (a total of at least 1,680 minutes).

MOOD study demographics and baseline data

The study included, in the main analysis population (mITT), 97 participants with major depressive disorder (MDD) (72 females and 25 males) who did not achieve satisfactory improvement from previous antidepressant medications in the current episode. All the participants in the mITT population exhibited compliance (following the treatment instructions as prescribed) with the prescribed treatment regimen. The participants were enrolled at 13 sites in the US and Israel. Baseline demographics were consistent with an MDD population in terms of age, gender, race, body mass index (BMI), education, employment status and head circumference. 74% (72/97) of the participants were female. The mean (average) age was 47.9 years (SD = 12.96 [SD means standard deviation, which shows how spread out the ages were]). The mean age in which the first depression episode occurred was 25.9 (SD = 13.6) years and ranged from 8 to 67 years. The number of antidepressant medications with no or insufficient response (that did not provide enough improvement) in the current episode was 1.8 (SD =0.89) and the mean current depression episode duration (the length of time the person has been experiencing their current depression episode) was 14 months (SD = 7.81). 62.9% (61/97) of the participants received psychotherapy treatment (talk therapy with a mental health professional) and all subjects were using antidepressant medications prior to and throughout the trial.

Assessment of blinding, which indicates whether the research participants knew whether they had the active or sham device, was performed after the first use of the device.

Effectiveness outcomes

The primary outcome was the change in depressive symptoms from baseline to week-8 post Proliv™Rx treatment initiation as measured by HDRS17 total score in the modified intent to treat (mITT) analysis group (n=97).

The active group (participants who received the real Proliv™Rx treatment) showed an 8.62-point reduction from the baseline following the 8-week-long treatment period while the sham group showed a corresponding reduction of 6.01 points. The group difference translates to a statistically significant 2.61-point therapeutic gain (p-value=0.0196). Therefore, the study was deemed successful.

ITT (n=124):
All randomized participants

mITT (n=97):
Participants without enrollment criteria violations who completed the minimal treatment time



Figure 17: **Change from Baseline in HDRS17 Regression Model Results - ITT and mITT analysis set**

The active arm was also compared to the sham arm across the following secondary endpoints; no statistically significant differences were detected under the prespecified Benjamini-Hochberg procedure.

- Remission rate - the percent of participants with HDRS17 score ≤7 at 8 weeks post treatment initiation. The observed remission rate was higher in the active arm in comparison with the sham arm, 21.3% (10/47) versus 6% (3/50) respectively.
- Responder rate - the percent of participants achieving at least 50% reduction from baseline in their HDRS17 total score, 8 weeks post treatment initiation. The observed response rate was greater in the active treatment group (31.9%, 15/47) than in the sham control group (18.0%, 9/50).
- Mean change in MADRS total score from baseline to week 8 post treatment initiation – The observed mean (SD) changes in MADRS total score were -10.3 (8.07) and -8.3 (8.03) for the active treatment and sham control groups, respectively.

In addition, favorable trends were observed for the following tertiary endpoints:

- HDRS17 clinically substantial improvement – defined as a reduction of at least 7 points. This level of improvement was attained in 61.7% (29/47) of the active treatment group compared with 32.0% (16/50) of the sham control group.
- HDRS17 category shift to lower depression severity. While none of the participants were considered Mild or in Remission at baseline, after 8 weeks of treatment 51% (24/47) of the participants in the active group were considered Mild or in Remission, compared to only 26% (13/50) in the sham group.

Open Label Phase

Participants who continued from the active group to the open label phase of the study, for a total of 16 active treatment weeks, showed continued improvement and benefits with increasing rates of response and remission up to the end of the study. Furthermore, participants who transitioned from the sham group to the active group after completing the double-blind phase improved significantly over the eight weeks treatment of the open-label phase. Although these results are difficult to interpret due to the absence of sham control for placebo effects in this extension of the study, the open-label phase provides additional information regarding the effectiveness of the active Proliv™Rx treatment.

Clinical Study Conclusions

Proliv™Rx demonstrated effectiveness in reducing depressive symptoms in adults with an inadequate response to prior antidepressant medications.

Reporting adverse events

MedWatch is the FDA's program for reporting serious side effects, product quality issues, treatment failures, and use errors involving medical products, including medicines, biologics, medical devices, dietary supplements, infant formula, and cosmetics.
If you experience a serious reaction, you can submit the online reporting form.
The FDA will confirm receipt of your report and contact you if additional information is needed.

Submitting Adverse Event Reports to FDA

Use one of the methods below to submit voluntary adverse event reports to the FDA:

- Report Online at: www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.homm
- Consumer Reporting Form FDA 3500B. Follow the instructions on the form to either fax or mail it in for submission. For help filling out the form, see MedWatchLearn.
- The form is available at: www.fda.gov/downloads/aboutFDA/reportsmanualsforms/forms/ucm349464.pdf
- Call FDA at 1-800-FDA-1088 to report by telephone.
- Reporting Form FDA 3500 is commonly used by health professionals. The form is available at www.fda.gov/downloads/aboutFDA/reportmanualsforms/forms/ucm163919.pdf

Proliv™ Rx
by Neurolief

Neurolief Ltd. | 12 Giborei Israel Netanya, Israel | Tel: +972-9-3730288

MAN1006A Rev.11 February 2026